Nomination committee appointed in IRLAB

September 20, 2017

In preparation for the annual general meeting 2018, the company’s three largest shareholders, or groups of shareholders, have appointed members of the nomination committee. The nomination committee consists of Bo Rydlinger, Erik Klinton and John D. Wakely beside Anders Vedin, the chairman of the board. The nomination committee represents more than 40 per cent of shares and votes in the company.

[mfn_before_post]

In preparation for the annual general meeting 2018, the company’s three largest shareholders, or groups of shareholders, have appointed members of the nomination committee. The nomination committee consists of Bo Rydlinger, Erik Klinton and John D. Wakely beside Anders Vedin, the chairman of the board. The nomination committee represents more than 40 per cent of shares and votes in the company.

According to the instruction for appointment of the nomination committee in IRLAB Therapeutics AB that was resolved at the annual general meeting on May 16, 2017, the nomination committee shall, besides the chairman of the board, consist of representatives of the three largest shareholders, or groups of shareholders, as per August 31.

As the three largest shareholders or groups of shareholders now have appointed their representatives, the nomination committee consists of the following members:

  • Bo Rydlinger, many years’ experience from banking and investments, appointed by a group of shareholders representing more than 17 per cent of shares and votes,
  • Erik Klinton, lawyer specialised in tax law, appointed by a group of shareholders that consists of the company’s founders representing more than 13 percent of shares and votes,
  • John D. Wakely, based in the UK with long experience from international financial markets, appointed by Sievert Larsson Scholarship Foundation which own 10 per cent of shares and votes, and
  • Anders Vedin, chairman of the board of IRLAB Therapeutics AB.

Information about the nomination committee’s work and the instruction to the nomination committee can be found on the company webside www.irlab.se/corporate-governance/nomination-committee/. The nomination committee’s proposal will be presented in the notice to the annual general meeting 2018 and on the company’s web page, www.irlab.se.

Shareholders who wish to submit proposals to the nomination committee may contact the nomination committee at the company’s address or e-mail – info@irlab.se. In order to enable the nomination committee to take proposals into consideration they must be submitted in good time prior to the annual general meeting and no later than January 31, 2018.

For more information

Anders Vedin, chairman of the board
Phone: +46 70 876 15 70
E-mail: anders.vedin@irlab.se

About IRLAB

IRLAB is a research and development company, listed on First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.

IRLAB currently runs programs with two candidate drugs, IRL752 and IRL790, both prepared for Phase II clinical studies, and three programs in pre-clinical phase. IRLAB’s research is aimed at regularly produce new candidate drugs using the unique and proprietary integrative research platform, ISP.

IRLAB is based in Gothenburg, Sweden. The operations is mainly carried out through the subsidiary Integrative Research Laboratories Sweden AB.

For more information, please visit www.irlab.se. 

[mfn_after_post]

Documents & Links